Behavioral and Cognitive Therapies for Auditory Hallucination Management

Not Applicable

Completed

• Conditions: Chronic Psychosis
• Interventions: Behavioral: Behavioral and Cognitive Therapies

• Registration Number: NCT03348787
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

The present study wants to evaluate the efficacy of a short psychoeducational type group intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory Acoustico-Verbal (HAV) symptomatology in patients with schizophrenia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-11-14
• Study First Submitted QC: 2017-11-17
• Study First Posted: 2017-11-21
• Study Start: 2017-12-13
• Primary Completion: 2019-12-05
• Study Completion: 2020-06-30
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-29
• Last Update Posted: 2020-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• Schizophrenic disorders, schizo-affective disorders
• Suffering from persistent HAV
• No change in symptomatology for 3 months.
• No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine, risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol, modecate, nozinan, cyamemazine, piportil, clozapine
• Major patient, or major incompetent.

Exclusion Criteria

• Mental retardation
• Subject participating in another search including an exclusion period still in progress at pre-inclusion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Behavioral and Cognitive Therapies	Behavioral and Cognitive Therapies	Chronic psychotic patients will have Behavioral and Cognitive Therapies

Primary Outcome Measures

Name	Time	Method
intensity HAV symptoms	Baseline and one week after the last session	Difference between the Psychotic Symptom Rating Scales (PSYRATS) on HAV symptom score administered before the first therapeutic group session and the PSYRATS symptom score administered 1 week after the last group session. The PSYRATS Scales measure dimensions of hallucinations and delusions.

Secondary Outcome Measures

Name	Time	Method
Effect over time	Until 12 months after the last session	Difference between the PSYRATS score given 1 week before the first session, and the PSYRATS score administered one week after the last session and then at 6 weeks, 6 months and 12 months.

Trial Locations

Locations (5)

Sainte-Marie de Rodez Hospital; 🇫🇷 Rodez, France

Ariège-Couserans Hospital; 🇫🇷 Saint-Lizier, France

Gérard Marchand Hospital; 🇫🇷 Toulouse, France

Lannemezan Hospital; 🇫🇷 Lannemezan, France

Lavaur Hospital; 🇫🇷 Lavaur, France